- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02014506
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents
March 24, 2017 updated by: Ho Joon Im, Asan Medical Center
Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of TCRαβ-depleted graft from haploidentical family donors in treating children and adolescents with malignant or non-malignant diseases.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ho Joon Im, MD, PhD
- Phone Number: 82-2-3010-3371
- Email: hojim@amc.seoul.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 138-736
- Recruiting
- Asan Medical Center
-
Contact:
- Ho Joon Im, MD & PhD
- Phone Number: 82-2-3010-3371
- Email: hojim@amc.seoul.kr
-
Principal Investigator:
- Ho Joon Im, MD & PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
A. Disease inclusions
Hematologic malignancy:
- Acute lymphoblastic leukemia including induction failure, CR1 (Ph+, t(4:11), hypodiploid and other very high risk features), ≥ CR2, infant ALL with MLL or other unfavorable features
- Acute myeloid leukemia excluding CR1 with t(8:21), inv(16), t(15:17), and Down syndrome
- Myelodysplastic syndrome: RCC with -7 or RCC in need of transfusion
- Chronic myeloid leukemia in AP
- Juvenile myelomonocytic leukemia
- Malignant lymphoma, NHL or HD, after failed autologous HSCT
- Other
Non-hematologic malignancy
- Relapsed or refractory solid tumors including neuroblastoma, rhabdomyosarcoma and so on
Non-malignant hematologic disease
- Acquired severe and very severe aplastic anemia
- Fanconi anemia
- Paroxysmal nocturnal hemoglobinuria
- Congenital dyserythropoietic anemia
- Others
Inherited or metabolic disease
- Hemophagocytic lymphohistiocytosis
- Malignant osteopetrosis
- Storage diseases
- Others B. Recipient inclusions
1. Age < 21 years 2. No HLA-identical stem cell donor available 3. Lansky-Play performance score >60 4. No active infection at the time of transplantation
Exclusion Criteria:
- HIV-infection
- Presence of active and serious infection
- Cardiac ejection fraction <35% on echocardiography
- Severe pulmonary dysfunction (DLCO <30%)
- Liver function abnormalities with bilirubin >4mg/dL and elevation of transaminases > 400U/L
- Concurrent severe or uncontrolled medical disease
- Patients who are pregnant
- Patients unwilling or unable to comply with the protocol or unable to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAPLO
|
40mg/M2 once daily IV on days -7 to -2
50 mg/kg IV on day -3 and -2
Beginning on day 4 and continuing until blood counts recover
200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)
Immunogenetic depletion of TCRαβ cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate tralsplant-related mortality after haploidentical hematopoietic stem cell transplantation using TCRαβ-depleted graft
Time Frame: 1 year posttransplant
|
1 year posttransplant
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess engraftment and graft failure
Time Frame: 28 days posttransplant
|
28 days posttransplant
|
To estimate the risk of acute GVHD
Time Frame: 100 days posttransplant
|
100 days posttransplant
|
To estimate the incidence of relapse
Time Frame: 100 days and 1 year post-transplant
|
100 days and 1 year post-transplant
|
To estimate the incidence and severity of chronic GVHD
Time Frame: 1 year posttransplant
|
1 year posttransplant
|
To estimate the overall survival
Time Frame: 1 year posttransplant
|
1 year posttransplant
|
To estimate the incidence of bacterial, fungal and viral infection
Time Frame: 100 days and 1 year posttransplant
|
100 days and 1 year posttransplant
|
To estimate the reactivation rate of CMV, EBV
Time Frame: 100 days and 1 year posttransplant
|
100 days and 1 year posttransplant
|
To evaluate the immune reconstitution of T, B, and NK cells
Time Frame: days 7, 14, 21, 28, 60, 90, 180, 270, and 365 days post-transplant
|
days 7, 14, 21, 28, 60, 90, 180, 270, and 365 days post-transplant
|
To evaluate the lineage-specific chimerism using flow cytomery of CD3+, CD19, CD56, TCR αβ, and TCRγδ at pre-transplant
Time Frame: days 7, 10, 14, 21, 28, 60, 90, 180, 270 and 365 post-transplant
|
days 7, 10, 14, 21, 28, 60, 90, 180, 270 and 365 post-transplant
|
To assess event free survival
Time Frame: 1 year posttransplant
|
1 year posttransplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ho Joon Im, MD, PhD, Asan Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Park JA, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ, Im HJ. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant. 2014 Feb;49(2):270-5. doi: 10.1038/bmt.2013.163. Epub 2013 Oct 21.
- Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, Chi HS, Seo JJ. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2013 May;19(5):754-9. doi: 10.1016/j.bbmt.2013.01.023. Epub 2013 Feb 1.
- Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, Vogel W, Huppert V, Handgretinger R. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013 Oct;15(10):1253-8. doi: 10.1016/j.jcyt.2013.05.014.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
December 4, 2013
First Submitted That Met QC Criteria
December 12, 2013
First Posted (Estimate)
December 18, 2013
Study Record Updates
Last Update Posted (Actual)
March 28, 2017
Last Update Submitted That Met QC Criteria
March 24, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMCPHO-SCT1303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haploidentical Hematopoietic Stem Cell Transplantation
-
Samsung Medical CenterRecruitingHaploidentical Hematopoietic Stem Cell TransplantationKorea, Republic of
-
Laurent KaiserActive, not recruitingHaploidentical Hematopoietic Stem Cell TransplantationSwitzerland
-
Chinese PLA General HospitalRecruitingHaploidentical Hematopoietic Stem Cell TransplantationChina
-
Chinese PLA General HospitalActive, not recruitingHaploidentical Hematopoietic Stem Cell TransplantationChina
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCCompletedHematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Hematopoietic | Transplantation, Hematopoietic Stem CellUnited States
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Peking University People's HospitalCompletedHaploidentical Hematopoietic Stem Cell TransplantationChina
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingConditioning | Haploidentical Stem Cell TransplantationChina
Clinical Trials on anti-thymocyte globulin
-
University of CincinnatiGenzyme, a Sanofi CompanyCompletedRenal Transplant Rejection | Transplants and ImplantsUnited States
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital Research... and other collaboratorsCompletedSafety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation (STAT)End-Stage Renal Disease | Kidney FailureUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Genzyme, a Sanofi CompanyCompletedMyelodysplastic SyndromesUnited States, Canada
-
M.D. Anderson Cancer CenterCompletedChronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
Genzyme, a Sanofi CompanyTerminatedMyelodysplastic Syndrome (MDS)Germany, United Kingdom, France, Netherlands
-
Hospital de Clinicas de Porto AlegreCompletedImmunosuppression | Kidney Transplant; ComplicationsBrazil
-
University of California, Los AngelesGenzyme, a Sanofi CompanyWithdrawnHeart Transplantation | Ischemia Reperfusion InjuryUnited States
-
European Institute of OncologyIstituto Clinico HumanitasTerminated
-
Swedish Medical CenterGenzyme, a Sanofi CompanyCompletedImmunosuppression | Renal TransplantationUnited States